Physician profile
Jonathan A Hatton
NPI 1629362397
$2,905.68
in general payments reported to CMS, 2019-2025
35 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.47 · 2020: $199 · 2021: $280 · 2022: $472 · 2023: $830 · 2024: $702 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $568.16 | 2021-2024 | |
| Indivior INC. | $546.41 | 2022-2025 | Sublocade |
| Lilly USA, LLC | $210.02 | 2020-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $172.46 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $150.45 | 2020-2024 | Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.19 | 2023-2025 | Caplyta |
| Braeburn INC. | $94.23 | 2023-2024 | Brixadi |
| Pfizer INC. | $92.16 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $90.91 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.69 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.54 | 2021-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $67.31 | 2023-2024 | Abilify Maintena, Rexulti |
| Amgen INC. | $62.96 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $61.03 | 2021-2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $57.49 | 2019-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $56.04 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $43.78 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.48 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.60 | 2023-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $29.02 | 2021 | |
| Kvk-Tech, INC. | $27.69 | 2024 | |
| Vanda Pharmaceuticals INC. | $23.09 | 2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $21.65 | 2024 | Auvelity |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Exact Sciences Corporation | $20.00 | 2023 | Cologuard Collection Kit |
| Lundbeck LLC | $19.94 | 2020 | |
| Amarin Pharma, INC. | $19.78 | 2019 | |
| Sunovion Pharmaceuticals INC. | $18.54 | 2022 | |
| Owp Pharmaceuticals, INC. | $16.54 | 2020 | |
| Melinta Therapeutics, LLC | $15.74 | 2022 | |
| Grifols USA, LLC | $14.87 | 2022 | |
| Merck Sharp & Dohme LLC | $14.38 | 2025 | Zerbaxa |
| Phathom Pharmaceuticals, INC. | $13.44 | 2025 | Voquezna |
| Pear Therapeutics (US), INC. | $11.89 | 2021 | |
| Allergan, INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hatton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.